26 May 2020
Deals | France | M&A | Private Equity
Gide has advised investment fund Remiges Ventures on its investment in biopharmaceutical company Phost'in Therapeutics, which specialises in the discovery and development of N-glycosylation inhibitors for cancer treatment.
This investment was part of a Series A funding round of EUR 10.3 million, alongside Japanese fund ANRI and Irdi Soridec Gestion.
The transaction was completed on 9 April 2020.
Gide's team advising Remiges Ventures comprised counsel Louis Oudot de Dainville and associate Marc Fournier on Corporate / M&A matters.